Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Abbott Receives European Regulatory Approval for New Ovarian Cancer DiagnosticTest

By Pharmaceutical Processing | January 14, 2010

A new diagnostictool, which studies show can aid in determining the risk of whether a pelvicmass is benign or malignant, is now available in Europe. This simple bloodtest is expected to help in the assessment of epithelial ovarian cancer, themost lethal form of gynecological cancer. This important immunoassay, whichwill run on Abbott’s ARCHITECT systems, is the first automated HE4 testavailable anywhere in the world. Research has shown that this novel diagnostic marker, combined with othertests such as the CA125 assay, can aid in measuring the risk of epithelialovarian cancer in pre- and post-menopausal women who have a pelvic mass.According to the International Agency for Research on Cancer, thefive-year survival rate of ovarian cancer patients is 46 percent. However,when the disease is diagnosed earlier, the survival rate increases to 94percent. “The ability of this test to help physicians predict whether a pelvic massis benign or malignant is an important development for both patients andphysicians,” said Michael Warmuth, senior vice president, diagnostics, Abbott.”Abbott’s ARCHITECT HE4 test will aid physicians in determining the mostappropriate treatment for their patients.” Abbott partnered with Fujirebio Diagnostics, Inc. in the development ofthe assay. The test is now available in several European countries, as well asin some countries in Asia Pacific and Latin America. The ARCHITECT HE4 Assaywas recently submitted to the FDA for 510(k) clearance.

Related Articles Read More >

FDA logo
FDA prevented 317 drug shortages in 2021
Pfizer-BioNTech vaccine vial
Pfizer, BioNTech moving forward on seeking COVID-19 vaccine EUA for youngest children
FDA logo
FDA curtails use of Janssen COVID-19 vaccine over blood clotting concerns
FDA logo
FDA sends warning letters to CBD and delta-8 THC product vendors

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards